Gland Pharma Balance Sheet Health
Financial Health criteria checks 5/6
Gland Pharma has a total shareholder equity of ₹87.9B and total debt of ₹2.8B, which brings its debt-to-equity ratio to 3.2%. Its total assets and total liabilities are ₹108.7B and ₹20.8B respectively. Gland Pharma's EBIT is ₹8.9B making its interest coverage ratio -7. It has cash and short-term investments of ₹28.2B.
Key information
3.2%
Debt to equity ratio
₹2.79b
Debt
| Interest coverage ratio | -7x |
| Cash | ₹28.20b |
| Equity | ₹87.88b |
| Total liabilities | ₹20.79b |
| Total assets | ₹108.67b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 543245's short term assets (₹64.0B) exceed its short term liabilities (₹15.4B).
Long Term Liabilities: 543245's short term assets (₹64.0B) exceed its long term liabilities (₹5.4B).
Debt to Equity History and Analysis
Debt Level: 543245 has more cash than its total debt.
Reducing Debt: 543245's debt to equity ratio has increased from 0.2% to 3.2% over the past 5 years.
Debt Coverage: 543245's debt is well covered by operating cash flow (437.2%).
Interest Coverage: 543245 earns more interest than it pays, so coverage of interest payments is not a concern.